| 23240926 | Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. | Thyroid | 2013 Jan | Ciampi R | doi: 10.1089/thy.2012.0207 |
| 28025078 | Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer. | Hum Pathol | 2017 Apr | Reggiani Bonetti L | doi: 10.1016/j.humpath.2016.12.011 |
| 27916952 | High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer. | Int J Mol Sci | 2016 Dec 1 | Jeantet M | - |
| 28100394 | Replication Study: Melanoma genome sequencing reveals frequent PREX2 mutations. | Elife | 2017 Jan 19 | Horrigan SK | doi: 10.7554/eLife.21634. |
| 26393682 | The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth. | Oncotarget | 2015 Oct 20 | Hameiri-Grossman M | doi: 10.18632/oncotarget.5616. |
| 18323787 | Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. | J Invest Dermatol | 2008 Aug | Houben R | doi: 10.1038/jid.2008.30 |
| 19492075 | Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. | PLoS One | 2009 May 27 | Jaiswal BS | doi: 10.1371/journal.pone.0005717. |
| 22926523 | GAB2 induces tumor angiogenesis in NRAS-driven melanoma. | Oncogene | 2013 Aug 1 | Yang Y | doi: 10.1038/onc.2012.367 |
| 26597176 | Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis. | BMC Cancer | 2015 Nov 23 | Weiss S | doi: 10.1186/s12885-015-1927-0. |
| 23922205 | Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. | Cancer | 2013 Nov 1 | Bucheit AD | doi: 10.1002/cncr.28306 |
| 25722211 | A Murine Model for Metastatic Conjunctival Melanoma. | Invest Ophthalmol Vis Sci | 2015 Apr | de Waard NE | doi: 10.1167/iovs.14-15239. |
| 18567617 | Silencing of N-Ras gene expression using shRNA decreases transformation efficiency and tumor growth in transformed cells induced by anti-BPDE. | Toxicol Sci | 2008 Oct | Zhou L | doi: 10.1093/toxsci/kfn122 |
| 19954345 | Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish. | Zebrafish | 2009 Dec | Dovey M | doi: 10.1089/zeb.2009.0606. |
| 23423222 | RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST. | Mol Cancer Res | 2013 Jun | Sun D | doi: 10.1158/1541-7786.MCR-12-0593 |
| 19101897 | Mutations of RAS gene family in specimens of bladder cancer. | Urol J | 2008 Fall | Karimianpour N | - |
| 22589270 | A comprehensive survey of Ras mutations in cancer. | Cancer Res | 2012 May 15 | Prior IA | doi: 10.1158/0008-5472.CAN-11-2612. |
| 22427190 | Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. | Int J Biol Markers | 2012 Jan-Mar | Bagadi SB | doi: 10.5301/JBM.2012.9108. |
| 26560143 | Absolute Quantification of Endogenous Ras Isoform Abundance. | PLoS One | 2015 Nov 11 | Mageean CJ | doi: 10.1371/journal.pone.0142674 |
| 19789336 | RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects. | Cancer Res | 2009 Oct 15 | Kreeger PK | doi: 10.1158/0008-5472.CAN-09-1921 |
| 24710085 | BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma. | Appl Immunohistochem Mol Morphol | 2015 Mar | Chiappetta C | doi: 10.1097/PAI.0000000000000071. |
| 21586752 | Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner. | Blood | 2011 Jul 14 | Wang J | doi: 10.1182/blood-2010-12-326058 |
| 14695152 | NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. | Clin Cancer Res | 2003 Dec 15 | Omholt K | - |
| 28341702 | NRAS destines tumor cells to the lungs. | EMBO Mol Med | 2017 May | Giannou AD | doi: 10.15252/emmm.201606978. |
| 27382031 | Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. | Oncologist | 2016 Aug | Moretto R | doi: 10.1634/theoncologist.2016-0084 |
| 27741509 | MEK1 is required for the development of NRAS-driven leukemia. | Oncotarget | 2016 Dec 6 | Nowacka JD | doi: 10.18632/oncotarget.12555. |
| 26575115 | Genetic Alterations in Differentiated Thyroid Cancer Patients with Acromegaly. | Exp Clin Endocrinol Diabetes | 2016 Mar | Aydin K | doi: 10.1055/s-0035-1565061 |
| 28259994 | Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer. | Int J Mol Med | 2017 Apr | Bai S | doi: 10.3892/ijmm.2017.2903 |
| 27356691 | Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer. | Asian Pac J Cancer Prev | 2016 | Pandith AA | - |
| 20619739 | Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. | Lancet Oncol | 2010 Aug | De Roock W | doi: 10.1016/S1470-2045(10)70130-3 |
| 24774510 | Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. | BMC Res Notes | 2014 Apr 29 | Takahashi N | doi: 10.1186/1756-0500-7-271. |
| 20192584 | Screening of N-ras gene mutations in urothelial cell carcinomas of the urinary bladder in the Kashmiri population. | Asian Pac J Cancer Prev | 2009 | Pandith AA | - |
| 23821376 | Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. | Target Oncol | 2014 Jun | Di Bartolomeo M | doi: 10.1007/s11523-013-0283-8 |
| 24806883 | Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations. | Oncol Rep | 2014 Jul | Ogura T | doi: 10.3892/or.2014.3165 |
| 26049686 | Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. | Eur J Cancer | 2015 Sep | Peeters M | doi: 10.1016/j.ejca.2015.05.017 |
| 26220150 | Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. | Cancer Treat Rev | 2015 Sep | Hecht JR | doi: 10.1016/j.ctrv.2015.05.008 |
| 24806288 | Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. | Int J Cancer | 2015 Jan 1 | Schirripa M | doi: 10.1002/ijc.28955 |
| 24024839 | Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. | N Engl J Med | 2013 Sep 12 | Douillard JY | doi: 10.1056/NEJMoa1305275. |
| 25491172 | RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. | Cancer | 2015 Apr 15 | Yaeger R | doi: 10.1002/cncr.29196 |
| 25164765 | Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. | Genome Biol | 2014 Aug 28 | Brannon AR | doi: 10.1186/s13059-014-0454-7. |
| 25997687 | RAS status in Korean patients with stage III and IV colorectal cancer. | Clin Transl Oncol | 2015 Sep | Lee WS | doi: 10.1007/s12094-015-1301-3 |
| 26799184 | Comparison of liver oncogenic potential among human RAS isoforms. | Oncotarget | 2016 Feb 9 | Chung SI | doi: 10.18632/oncotarget.6931. |
| 26325669 | Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. | Oncotarget | 2015 Sep 22 | Formisano L | doi: 10.18632/oncotarget.4636. |
| 25851630 | Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. | Ann Oncol | 2015 Aug | Normanno N | doi: 10.1093/annonc/mdv176 |
| 24691006 | Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. | PLoS One | 2014 Apr 1 | Pietrantonio F | doi: 10.1371/journal.pone.0092147 |
| 25666295 | FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. | Clin Colorectal Cancer | 2015 Jun | Kaczirek K | doi: 10.1016/j.clcc.2014.12.003 |
| 27737491 | Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. | Cancer | 2017 Feb 15 | Frankel TL | doi: 10.1002/cncr.30351 |
| 28074351 | KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. | Med Oncol | 2017 Feb | Cicenas J | doi: 10.1007/s12032-016-0879-9 |
| 28202657 | Deciphering the RAS/ERK pathway in vivo. | Biochem Soc Trans | 2017 Feb 8 | Dorard C | doi: 10.1042/BST20160135. |
| 28864536 | Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer. | Eur J Endocrinol | 2017 Dec | Song YS | doi: 10.1530/EJE-17-0456 |
| 28859058 | Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. | Br J Cancer | 2017 Oct 24 | Gollins S | doi: 10.1038/bjc.2017.294 |
| 28249840 | New Guideline on Managing Colorectal Cancer. | Cancer Discov | 2017 Apr | - | doi: 10.1158/2159-8290.CD-NB2017-030 |
| 26989027 | Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. | Oncotarget | 2016 Apr 19 | Hsu HC | doi: 10.18632/oncotarget.8076. |
| 27191502 | NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand. | Oncotarget | 2016 Jul 5 | Jones AM | doi: 10.18632/oncotarget.9351. |
| 28378457 | DNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancer. | Cancer Med | 2017 May | Takane K | doi: 10.1002/cam4.1061 |
| 27636997 | Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. | Oncotarget | 2016 Dec 13 | Queralt B | doi: 10.18632/oncotarget.11985. |
| 29335867 | Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer? | Eur Radiol | 2018 May | Yang L | doi: 10.1007/s00330-017-5146-8 |
| 29495918 | MicroRNA-29a Functions as a Tumor Suppressor and Increases Cisplatin Sensitivity by Targeting NRAS in Lung Cancer. | Technol Cancer Res Treat | 2018 Jan 1 | Liu X | doi: 10.1177/1533033818758905. |
| 29976257 | Differences in gene mutations according to gender among patients with colorectal cancer. | World J Surg Oncol | 2018 Jul 5 | Tsai YJ | doi: 10.1186/s12957-018-1431-5. |
| 30562355 | Analysis of KRAS, NRAS and BRAF mutational profile by combination of in-tube hybridization and universal tag-microarray in tumor tissue and plasma of colorectal cancer patients. | PLoS One | 2018 Dec 18 | Damin F | doi: 10.1371/journal.pone.0207876 |
